Manejo de neumonía por sars-cov-2 en adultos varones

Abstract

Introduction: Pneumonia due to SARS-CoV-2 infection is particularly worrying due to its ability to severely affect the lungs and cause severe symptoms in a significant percentage of patients Objective: Establish the management of pneumonia SARS-CoV 2, to provide better health care. Methodology: We conducted searches in academic and scientific databases, such as PubMed, Google Scholar and Scielo, using search terms such as "Covid-19", "SARS-CoV-2", "pneumonia", "management", "treatment". We selected articles published in indexed journals during the period from 2018 to 2023, which specifically address the management of SARS-CoV-2 pneumonia. Development: In the management of SARS-CoV 2 pneumonia, patients with SaO2 oxygen saturation equal to or less than 92-93% and signs of polypnea, oxygen therapy and the decubitus prono have been shown to be effective in the early stages of disease and steroid use in patients with 92% SaO2. Remdesivir was shown to shorten recovery time in hospitalized patients with low respiratory infection due to VOCID-19; however, its impact on mortality has not been decisive. Management of the excessive inflammatory response associated with COVID-19, known as cytokine storm, is addressed with therapies such as Tocilizumab, an IL-6 inhibitor, and corticosteroids. Conclusion: Management varies according to the severity of the disease. Patients with mild pneumonia may be treated in outpatient settings or at home, while moderate or severe cases should be hospitalized.